FUNDAMENTALS |
MarketCap: |
0.950 mill
|
EPS: |
-94.13
|
P/E: |
-0.0002
|
Earnings Date: |
May 09, 2024 |
SharesOutstanding: |
43.59 mill
|
Avg Daily Volume: |
0.425 mill
|
RATING
2024-02-29 |
B
|
Neutral
|
RATINGS |
Rating CashFlow: |
Strong Buy
|
|
Return On Equity: |
Strong Buy
|
|
Return On Asset: |
Neutral
|
|
DE: |
Strong Sell
|
|
P/E: |
Sell
|
|
Price To Book: |
Strong Sell
|
|
QUARTER GROWTHS |
|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE -0.0002 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
0.00x
|
Company: PE -0.0002 | industry: PE 5.88
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 0.0130 - 0.0210
( +/- 23.53%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2023-10-09 | Mcandrew Natalie | Buy | 0 | |
2023-07-03 | Kim Yong Chan | Sell | 0 | Common Stock |
2023-07-03 | Kim Yong Chan | Sell | 4 520 066 | Series X Preferred Stock |
2022-12-15 | Henwood Geraldine | Buy | 1 200 | Common Stock |
2022-06-15 | Ashton William | Buy | 39 473 | Common Stock |
INSIDER POWER |
-97.72
|
Last
86 transactions |
Buy:
13 000 393 | Sell:
13 896 192 |
Forecast:
16:00 - $0.0218
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.0218
Forecast 2: 16:00 - $0.0218
Forecast 3: 16:00 - $0.0218
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$0.0218 (7.39% )
|
Volume |
0.311 mill
|
Avg. Vol. |
0.425 mill
|
% of Avg. Vol |
73.17 %
|
Signal 1: |
|
Signal 2: |
|
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BXRX
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.